Helen Ruth Nadel, MD
Nuclear Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Lpch Medical Group Div of Lucile · Stanford Health Care
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Nadel’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence C156733 · Current
Licensed to practise in California · since 2018 · expires 2027-11-30 · University of Manitoba Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$621
Medicare paid this office $621 for 32 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| X-ray of chest, 1 view | 25 | $219 | $8 |
Who their Medicare patients are
32 Original Medicare patients in 2024. Average age 59 · Women 47% · Also on Medicaid 44% · Health risk score 2.50. Above the middle of the specialty; the typical nuclear medicine clinician is at 1.94.
Conditions among them: High blood pressure 75% · Chronic kidney disease 72% · Atrial fibrillation 66% · Heart failure 59% · Coronary heart disease 56% · Diabetes 47%.
The office billed $4,726, Medicare allowed $779 and paid $621; for 52 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 32 | 52 | 59 | 2.50 | $4,726 | $621 |
| 2023 | 77 | 90 | 69 | 2.80 | $9,748 | $874 |
| 2022 | 71 | 94 | 69 | 2.36 | $10,514 | $1,060 |
| 2021 | 48 | 59 | 59 | 3.34 | $8,224 | $831 |
| 2020 | 16 | 36 | 43 | 4.28 | $8,373 | $713 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| X-ray of chest, 1 view | 48 | $391 | $8 |
| X-ray of abdomen, 1 view | 20 | $171 | $8 |
2022: 2 services
| X-ray of chest, 1 view | 40 | $343 | $8 |
| X-ray of chest, 2 views | 11 | $108 | $10 |
2021: 1 service
| X-ray of chest, 1 view | 29 | $258 | $8 |
Medicaid work
$18,996 in 2024
Medicaid paid $18,996 for 972 billed services this clinician did in 2024, up to 51 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| US RETROPERITONEAL REAL TIME W/IMAGE COMPLETE | 83 | $6,797 |
| Radiologic examination, chest; single view | 661 | $6,714 |
| VASCULAR STUDY | 43 | $3,375 |
| X-ray of abdomen, 1 view | 147 | $1,473 |
| Radiologic examination, chest; 2 views | 26 | $319 |
| ECHO EXAM OF ABDOMEN | 12 | $317 |
| 2024 | 972 | 6 | 51 | $18,996 |
| 2023 | 1,271 | 9 | 74 | $22,642 |
| 2022 | 967 | 7 | 50 | $19,133 |
| 2021 | 1,389 | 7 | 53 | $20,621 |
| 2020 | 1,287 | 4 | 76 | $14,019 |
| 2019 | 1,234 | 5 | 69 | $12,114 |
| 2018 | 59 | 1 | 18 | $766 |
See the largest Medicaid services in earlier years
2023
| Radiologic examination, chest; single view | 794 | $7,481 |
| US RETROPERITONEAL REAL TIME W/IMAGE COMPLETE | 85 | $5,277 |
| ECHO EXAM OF ABDOMEN | 128 | $2,839 |
| VASCULAR STUDY | 30 | $2,588 |
| Ultrasound, abdominal, real time with image documentation; complete | 31 | $1,459 |
| X-ray of abdomen, 1 view | 129 | $1,368 |
| Radiologic examination, spine, entire thoracic and lumbar, including skull, cervical and sacral spine if performed (eg, scoliosis evaluation); 2 or 3 views | 17 | $635 |
| Echoencephalography, real time with image documentation (gray scale) (for determination of ventricular size, delineation of cerebral contents, and detection of fluid masses or other intracranial abnormalities), including A-mode encephalography as secondary component where indicated | 24 | $599 |
| Radiologic examination, chest; 2 views | 33 | $396 |
2022
| US RETROPERITONEAL REAL TIME W/IMAGE COMPLETE | 116 | $8,964 |
| Radiologic examination, chest; single view | 667 | $6,022 |
| VASCULAR STUDY | 14 | $1,380 |
| X-ray of abdomen, 1 view | 102 | $1,029 |
| ECHO EXAM OF ABDOMEN | 34 | $672 |
| Ultrasound, abdominal, real time with image documentation; complete | 17 | $649 |
| Echoencephalography, real time with image documentation (gray scale) (for determination of ventricular size, delineation of cerebral contents, and detection of fluid masses or other intracranial abnormalities), including A-mode encephalography as secondary component where indicated | 17 | $417 |
2021
| Radiologic examination, chest; single view | 1,029 | $8,590 |
| US RETROPERITONEAL REAL TIME W/IMAGE COMPLETE | 98 | $7,347 |
| X-ray of abdomen, 1 view | 169 | $1,492 |
| ECHO EXAM OF ABDOMEN | 30 | $1,010 |
| Ultrasound, abdominal, real time with image documentation; complete | 28 | $891 |
| VASCULAR STUDY | 15 | $708 |
| Echoencephalography, real time with image documentation (gray scale) (for determination of ventricular size, delineation of cerebral contents, and detection of fluid masses or other intracranial abnormalities), including A-mode encephalography as secondary component where indicated | 20 | $582 |
2020
| Radiologic examination, chest; single view | 992 | $10,072 |
| X-ray of abdomen, 1 view | 229 | $2,313 |
| US RETROPERITONEAL REAL TIME W/IMAGE COMPLETE | 12 | $890 |
| Radiologic examination, chest; 2 views | 54 | $744 |
2019
| Radiologic examination, chest; single view | 978 | $9,252 |
| X-ray of abdomen, 1 view | 201 | $1,926 |
| Radiologic examination, chest; 2 views | 30 | $397 |
| X-RAY EXAM OF PELVIS | 12 | $287 |
| ECHO EXAM OF ABDOMEN | 13 | $252 |
2018
| Radiologic examination, chest; single view | 59 | $766 |
Money from drug and device companies
$185 in 2025
| 2025 | 3 | 3 | None | $185 |
| 2024 | 1 | 1 | None | $144 |
| 2023 | 1 | 1 | None | $44 |
| 2022 | 1 | 1 | None | $69 |
| 2020 | 1 | 1 | None | $19 |
| 2019 | 1 | 8 | None | $174 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ge Healthcare | None | $107 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $47 | 1 payment
|
| Siemens Medical Solutions USA | Biograph Vision 600 (8 Ring/64 Ct) | $31 | 1 payment
|
See all 3 published payments
| Ge Healthcare | Meals · 2025-12-04 | None | $107 |
| Siemens Medical Solutions USA | Meals · 2025-08-04 | Biograph Vision 600 (8 Ring/64 Ct) | $31 |
| Progenics Pharmaceuticals | Meals · 2025-03-08 | Pylarify | $47 |
See earlier years (2024, 2023, 2022, 2020, 2019)
2024: $144
| Ge Healthcare | None | $144 | 1 payment
|
2023: $44
| Novartis Pharmaceuticals | Cosentyx | $44 | 1 payment
|
2022: $69
| Novartis Pharmaceuticals | None | $69 | 1 payment
|
2020: $19
| Ge Healthcare | None | $19 | 1 payment
|
2019: $174
| Ge Healthcare | None | $174 | 8 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Y-mAbs Therapeutics, Inc. · A Pivotal Phase 2 Trial of Antibody Naxitamab (Hu3f8) and Granulocyte-Macrophage Colony Stimulating Factor (Gm-Csf) in High-Risk Neuroblastoma Patients With Primary Refractory Disease Or Incomplete Response To Salvage Treatment in Bone and/Or Bone Marrow · 2022 | This clinician | $5,245 |
| Y-mAbs Therapeutics, Inc. · A Pivotal Phase 2 Trial of Antibody Naxitamab (Hu3f8) and Granulocyte-Macrophage Colony Stimulating Factor (Gm-Csf) in High-Risk Neuroblastoma Patients With Primary Refractory Disease Or Incomplete Response To Salvage Treatment in Bone and/Or Bone Marrow · 2024 | This clinician | $4,760 |
| Y-mAbs Therapeutics, Inc. · A Pivotal Phase 2 Trial of Antibody Naxitamab (Hu3f8) and Granulocyte-Macrophage Colony Stimulating Factor (Gm-Csf) in High-Risk Neuroblastoma Patients With Primary Refractory Disease Or Incomplete Response To Salvage Treatment in Bone and/Or Bone Marrow · 2023 | This clinician | $4,420 |
| Y-mAbs Therapeutics, Inc. · A Pivotal Phase 2 Trial of Antibody Naxitamab (Hu3f8) and Granulocyte-Macrophage Colony Stimulating Factor (Gm-Csf) in High-Risk Neuroblastoma Patients With Primary Refractory Disease Or Incomplete Response To Salvage Treatment in Bone and/Or Bone Marrow · 2021 | This clinician | $850 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1750877262
- Licence
- CA C156733California C156733: Current · expires 2027-11-30
- Group
- Lpch Medical Group Div of Lucile · Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2085N0904X (2085N0904X); Federal specialty code 207U00000X (207U00000X); Federal specialty code 2085P0229X (2085P0229X); Diagnostic radiology (2085R0202X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2018-07-09
- NPI last updated
- 2024-04-08
- NPI record certified
- 2024-04-08
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 750 Welch Road, Stanford, CA, 94305